Source comparison
Thymosin Alpha-1: Clinical Context Comparison
Chronic Hepatitis B HBeAg seroconversion at 48 weeks +22% absolute increase (Cochrane 2018) CD8+ T-cell functional restoration HBeAg-positive, treatment-naive or partial responders Meaningful adjuvant. Not monotherapy Sepsis / Critical Illness 28-day all-cause
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B
- HBeAg seroconversion at 48 weeks
- +22% absolute increase (Cochrane 2018)
- CD8+ T-cell functional restoration
- HBeAg-positive, treatment-naive or partial responders
- Meaningful adjuvant. Not monotherapy
- Sepsis / Critical Illness
- 28-day all-cause mortality
- −14% relative risk reduction (only in lymphopenic subgroup)
- Reversal of septic immunoparalysis (HLA-DR recovery)
- Absolute lymphocyte count <0.8 × 10⁹/L
- Benefit limited to immunosuppressed phenotype
- NSCLC + Anti-PD-1
- Objective response rate
- +11% absolute increase
- Enhanced tumor-infiltrating lymphocyte function
- PD-L1+ tumors with baseline TIL presence
- Modest synergy in immunogenic tumors
- Melanoma + Checkpoint Inhibitor
- Overall survival at 2 years
- No significant difference (multiple trials)
- Attempted TIL expansion
- Any stage III/IV melanoma
- No consistent survival benefit shown
- COVID-19 Pneumonia
- Time to lymphocyte recovery
- 3–5 day reduction in normalization time
- Correction of virus-induced T-cell apoptosis
- Severe COVID with lymphocyte count <800/μL
- Faster immune recovery, unclear mortality impact